Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;84(16):1427-1433.
doi: 10.1002/pros.24781. Epub 2024 Aug 18.

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate

Eric V Li  1 , Matthew S Lee  2 , Jenny Guo  1 , Nicholas Dean  1 , Sai Kumar  1 , Xinlei Mi  1 , Ruoji Zhou  3 , Clayton Neill  1 , Ximing Yang  3 , Ashley E Ross  1 , Amy E Krambeck  1
Affiliations

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate

Eric V Li et al. Prostate. 2024 Dec.

Abstract

Background: To evaluate contemporary preoperative risk factors and subsequent postoperative management of incidental prostate cancer (iPCa) and incidental clinically significant prostate cancer (icsPCa, Grade Group [GG] ≥ 2 PCa).

Methods: A retrospective cohort of 811 men undergoing Holmium enucleation of the prostate (HoLEP) (January 2021-July 2022) were identified. Advanced preoperative testing was defined as prostate health index (PHI), prostate MRI, and/or negative preoperative biopsy. Descriptive statistics (Whitney-Mann U test, Chi-squared test) and multivariable logistic regression were performed.

Results: iPCa and icsPCa detection rates were 12.8% (104/811) and 4.4% (36/811), respectively. Advanced preoperative testing (406/811, 50%) was associated with younger age and higher (prostate specific antigen) PSA, prostate volume, and PSA density. On multivariable analysis, PHI ≥ 55 was associated with iPCa (OR 6.91, 95% CI 1.85-26.3, p = 0.004), and % free PSA (%fPSA) was associated with icsPCa (OR 0.83, 95% CI 0.67, 0.94, p = 0.01). GG1 disease comprised the majority of iPCa (65%, 68/104) with median 1% involvement. iPCa patients were followed with active surveillance (median follow up 9.3 months), with higher risk patients receiving prostate MRI and confirmatory biopsy. Three patients proceeded to radical prostatectomy or radiation.

Conclusions: In the era of MRI and advanced biomarkers, the majority of iPCa following HoLEP is low volume GG1 suitable for active surveillance. A tentative follow-up strategy is proposed. Patients with PHI ≥ 55 or low %fPSA, even with negative prostate MRI, can consider preoperative prostate biopsy before HoLEP.

Keywords: benign prostatic hyperplasia; genomics; holmium enucleation of the prostate; incidental prostate cancer; lower urinary tract symptoms; multiparametric prostate MRI.

PubMed Disclaimer

References

REFERENCES

    1. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms. Urol Clin North Am. 2016;43(3):289‐297.
    1. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline Part I–Initial work‐up and medical management. J Urol. 2021;206(4):806‐817.
    1. Ibrahim A, Alharbi M, Elhilali MM, Aubé M, Carrier S. 18 years of holmium laser enucleation of the prostate: a single center experience. J Urol. 2019;202(4):795‐800.
    1. Lee MS, Assmus MA, Guo J, Siddiqui MR, Ross AE, Krambeck AE. Relationships between holmium laser enucleation of the prostate and prostate cancer. Nat Rev Urol. 2022;20:226‐240.
    1. Nunez R, Hurd KJ, Noble BN, Castle EP, Andrews PE, Humphreys MR. Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol. 2011;18(7):543‐547.